Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma

BACKGROUND. Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC). Because of narrow trial eligibility, results may not be generalizable to a broader HCC population. We sought to evaluate the effectiveness of initial sorafenib versus no treatment among Medicare...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanoff, Hanna K., Chang, YunKyung, Lund, Jennifer L., O’Neil, Bert H., Dusetzina, Stacie B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Hepatobiliary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016063/
https://www.ncbi.nlm.nih.gov/pubmed/27185615
http://dx.doi.org/10.1634/theoncologist.2015-0478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016063/
https://www.ncbi.nlm.nih.gov/pubmed/27185615
http://dx.doi.org/10.1634/theoncologist.2015-0478

Ejemplares similares